Respimat

Respimat, or commonly referred to as Respimat SMI (SMI indicates "Soft Mist Inhaler").

Respimat SMI is an advanced drug delivery device in comparison to MDIs(Metered Dose Inhalers) or DPIs(Dry Powder Inhalers) used for the treatment of asthma, chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Its developer, Boehringer Ingelheim, is currently conducting Phase III clinical trials in the US with a variety of their products, such as Spiriva and Combivent.